# Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

> **NCT00487786** · PHASE1 · COMPLETED · sponsor: **Achieve Life Sciences** · enrollment: 64 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** OGX-427
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00487786
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-10
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00487786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00487786, "Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00487786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*